ArticleStem cells international2026
MSC-EVs Prevent Abdominal Aortic Aneurysm Formation by Inhibiting Perivascular Adipose Tissue-Induced NET Release.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MSC-EVs Prevent Abdominal Aortic Aneurysm Formation by Inhibiting Perivascular Adipose Tissue-Induced NET Release.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perivascular adipose tissue (PVAT) envelops arteries and exerts paracrine effects, thereby modulating cardiovascular pathologies. Nevertheless, its precise role in abdominal aortic aneurysm (AAAs) pathogenesis remains elusive. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been implicated in the regulation of neutrophil extracellular traps (NETs) formation. This investigation delineates PVAT's involvement in AAA, particularly in NETs regulation, and evaluates the modulatory impact of MSC-EVs on these processes. Methods: A comprehensive analysis of CT imaging and clinical datasets from AAA patients was undertaken. Subsequent RNA sequencing and transcriptomic profiling of PVAT from AAA animal models and controls were conducted. Both in vivo and in vitro assays were employed to determine whether PVAT-derived proteins influence NETs release within the abdominal aorta and contribute to AAA development. Additionally, MSC-EVs were administered via intravenous or intraperitoneal routes to assess their effects on PVAT accumulation and NETs formation. Results: A significant correlation was established between PVAT characteristics and clinical outcomes in AAA patients. Experimental findings reveal that PVAT-derived serum amyloid A (SAA) promotes PVAT accumulation and induces NETs release within the abdominal aorta during AAA formation. Intraperitoneal MSC-EVs administration mitigates AAA development by reducing PVAT accumulation, suppressing SAA expression in PVAT, and inhibiting NETs formation in the abdominal aorta. Conclusion: PVAT-derived SAA facilitates NETs formation during AAA pathogenesis. MSC-EVs, by targeting these mechanisms, offer a promising prophylactic strategy against AAA, opening new therapeutic avenues for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.